JO3713B1 - أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت - Google Patents
أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميتInfo
- Publication number
- JO3713B1 JO3713B1 JOP/2014/0088A JOP20140088A JO3713B1 JO 3713 B1 JO3713 B1 JO 3713B1 JO P20140088 A JOP20140088 A JO P20140088A JO 3713 B1 JO3713 B1 JO 3713B1
- Authority
- JO
- Jordan
- Prior art keywords
- quinuclidin
- thiazol
- propan
- fluorophenyl
- carbamate
- Prior art date
Links
- YFHRCLAKZBDRHN-MRXNPFEDSA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(N=1)=CSC=1C1=CC=C(F)C=C1 YFHRCLAKZBDRHN-MRXNPFEDSA-N 0.000 title abstract 2
- 150000003839 salts Chemical group 0.000 title abstract 2
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 abstract 2
- 108091000114 ceramide glucosyltransferase Proteins 0.000 abstract 2
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<span dir="RTL">يتعلق الاختراع الحالي بصور جديدة من ملح (</span>S<span dir="RTL">)-كينيوكليدين-3-يل(2-2-(4-فلوروفينيل)ثيازول-4-يل) بروبان-2-يل) كربامات مفيدة كمثبط لإنزيم جلوكوزيل سيراميد سينثاز (</span>GCS<span dir="RTL">) و لعلاج أمراض الأيض، مثل أمراض تخزين الجسيم الحال، سواء بمفرده أو بالترافق مع معالجة بالتعويض عن الإنزيمات، و لعلاج السرطان.</span>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791706P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3713B1 true JO3713B1 (ar) | 2021-01-31 |
Family
ID=50543351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2014/0088A JO3713B1 (ar) | 2013-03-15 | 2014-03-11 | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9518049B2 (ar) |
| EP (1) | EP2970250B1 (ar) |
| JP (1) | JP6438455B2 (ar) |
| KR (1) | KR102302064B1 (ar) |
| CN (1) | CN105189490A (ar) |
| AR (1) | AR095435A1 (ar) |
| AU (1) | AU2014240028B2 (ar) |
| BR (1) | BR112015022907B1 (ar) |
| CA (1) | CA2906691A1 (ar) |
| CL (1) | CL2015002701A1 (ar) |
| DK (1) | DK2970250T3 (ar) |
| EA (1) | EA037527B1 (ar) |
| ES (1) | ES2872326T3 (ar) |
| HR (1) | HRP20210692T1 (ar) |
| HU (1) | HUE054349T2 (ar) |
| IL (1) | IL241229B (ar) |
| JO (1) | JO3713B1 (ar) |
| LT (1) | LT2970250T (ar) |
| MA (1) | MA38488A1 (ar) |
| MX (1) | MX370178B (ar) |
| MY (1) | MY181766A (ar) |
| PH (1) | PH12015502021A1 (ar) |
| PL (1) | PL2970250T3 (ar) |
| PT (1) | PT2970250T (ar) |
| RS (1) | RS61852B1 (ar) |
| SA (1) | SA515361078B1 (ar) |
| SG (1) | SG11201507054YA (ar) |
| SI (1) | SI2970250T1 (ar) |
| TN (1) | TN2015000427A1 (ar) |
| TW (1) | TWI713438B (ar) |
| UY (1) | UY35439A (ar) |
| WO (1) | WO2014152215A1 (ar) |
| ZA (1) | ZA201506602B (ar) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| EP3079695B1 (en) * | 2013-12-11 | 2021-03-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
| SG11202107844UA (en) * | 2019-02-04 | 2021-08-30 | Genzyme Corp | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
| PT3920912T (pt) | 2019-02-04 | 2025-09-09 | Genzyme Corp | Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs) |
| IL295255A (en) | 2020-02-03 | 2022-10-01 | Genzyme Corp | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| IL300090A (en) | 2020-07-24 | 2023-03-01 | Genzyme Corp | Pharmaceutical preparations containing VENGLUSTAT |
| US20230372313A1 (en) | 2020-07-30 | 2023-11-23 | Genzyme Corporation | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
| WO2022215083A1 (en) * | 2021-04-05 | 2022-10-13 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof |
| CN120417900A (zh) | 2022-12-01 | 2025-08-01 | 建新公司 | 文鲁司他与cyp3a4的强或中度抑制剂的组合 |
| TW202604489A (zh) | 2024-04-19 | 2026-02-01 | 美商健臻公司 | 用於降低患有神經節苷脂儲積症的患者中的疾病相關生物標誌物水準之方法 |
| WO2025219952A1 (en) | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| TW202606667A (zh) | 2024-06-17 | 2026-02-16 | 美商健臻公司 | 使用葡萄糖神經醯胺合成酶抑制劑治療患有肝損傷之受試者的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| EP1027069B1 (en) | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| BRPI0517701A8 (pt) | 2004-11-10 | 2018-01-23 | Genzyme Corp | métodos de tratamento de diabetes mellitus |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| CA2773133A1 (en) | 2009-08-28 | 2011-03-03 | Edward H. Schuchman | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| LT2685986T (lt) | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
-
2014
- 2014-03-11 JO JOP/2014/0088A patent/JO3713B1/ar active
- 2014-03-13 AR ARP140100981A patent/AR095435A1/es unknown
- 2014-03-14 EA EA201591706A patent/EA037527B1/ru unknown
- 2014-03-14 MA MA38488A patent/MA38488A1/fr unknown
- 2014-03-14 UY UY0001035439A patent/UY35439A/es not_active Application Discontinuation
- 2014-03-14 MX MX2015012295A patent/MX370178B/es active IP Right Grant
- 2014-03-14 WO PCT/US2014/027081 patent/WO2014152215A1/en not_active Ceased
- 2014-03-14 MY MYPI2015702973A patent/MY181766A/en unknown
- 2014-03-14 CA CA2906691A patent/CA2906691A1/en not_active Abandoned
- 2014-03-14 SI SI201431813T patent/SI2970250T1/sl unknown
- 2014-03-14 ES ES14718854T patent/ES2872326T3/es active Active
- 2014-03-14 HU HUE14718854A patent/HUE054349T2/hu unknown
- 2014-03-14 EP EP14718854.4A patent/EP2970250B1/en active Active
- 2014-03-14 PT PT147188544T patent/PT2970250T/pt unknown
- 2014-03-14 US US14/776,432 patent/US9518049B2/en active Active
- 2014-03-14 CN CN201480025303.7A patent/CN105189490A/zh active Pending
- 2014-03-14 SG SG11201507054YA patent/SG11201507054YA/en unknown
- 2014-03-14 JP JP2016502330A patent/JP6438455B2/ja active Active
- 2014-03-14 PL PL14718854T patent/PL2970250T3/pl unknown
- 2014-03-14 HR HRP20210692TT patent/HRP20210692T1/hr unknown
- 2014-03-14 BR BR112015022907-7A patent/BR112015022907B1/pt active IP Right Grant
- 2014-03-14 DK DK14718854.4T patent/DK2970250T3/da active
- 2014-03-14 AU AU2014240028A patent/AU2014240028B2/en active Active
- 2014-03-14 KR KR1020157028855A patent/KR102302064B1/ko active Active
- 2014-03-14 RS RS20210607A patent/RS61852B1/sr unknown
- 2014-03-14 TW TW103109465A patent/TWI713438B/zh active
- 2014-03-14 LT LTEP14718854.4T patent/LT2970250T/lt unknown
-
2015
- 2015-09-06 IL IL241229A patent/IL241229B/en active IP Right Grant
- 2015-09-07 ZA ZA2015/06602A patent/ZA201506602B/en unknown
- 2015-09-09 PH PH12015502021A patent/PH12015502021A1/en unknown
- 2015-09-13 SA SA515361078A patent/SA515361078B1/ar unknown
- 2015-09-14 CL CL2015002701A patent/CL2015002701A1/es unknown
- 2015-09-15 TN TN2015000427A patent/TN2015000427A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000427A1 (en) | Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate | |
| MX2020002867A (es) | Inhibidores de glucosilceramida sintasa. | |
| MX2019008428A (es) | Inhibidores de glucosilceramida sintasa. | |
| SG10201804952QA (en) | Glucosylceramide synthase inhibitors | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| MX365464B (es) | Prodecimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| TN2013000368A1 (en) | Glucosylceramide synthase inhibitors | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| TH170238A (th) | รูปเกลือของ (s)-ควินิวคลิดิน-3-อิล (2-(2-(4-ฟลูออโรฟีนิล)ไทอาโซล-4-อิล)โพรเพน-2-อิล)คาร์บาเมต |